A pilot study for early evaluation and estimation of prognosis of patients with advanced and/or relapsed breast cancer by endocrine and/or CDK4/6 inhibitor combined therapy using estrogen receptor PET
Not Applicable
- Conditions
- Breast cancer
- Registration Number
- JPRN-UMIN000037327
- Lead Sponsor
- Saitama Medical University
- Brief Summary
We compared the values of the positive therapy response (RP) group (lesions with a decrease in the FDG SUVmax >=30% after treatment) and the negative therapy response (RN) group (lesions with a decrease in the FDG SUVmax <30%). The FES SUVmax was significantly different in both groups before (RPpre and RNpre) and after (RPpost and RNpost) treatment. The FES value was high before treatment and low after treatment. A decrease trend like FES changes was observed for the FDG SUVmax).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 8
Inclusion Criteria
Not provided
Exclusion Criteria
1. patients with the serum fasting glucose level is more than 150mg/dL at the day of entry 2. patients who entered to the other clinical trials 28 days before the day of entry
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the change rate of FDG-SUVmax
- Secondary Outcome Measures
Name Time Method Tumor mass reduction rate, effective rate, disease-free survival period, survival period, treatment success period